Gritstone Bio Debt to Equity Ratio 2017-2024 | GRTSQ
Current and historical debt to equity ratio values for Gritstone Bio (GRTSQ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Gritstone Bio debt/equity for the three months ending June 30, 2024 was 1.83.
| Gritstone Bio Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.12B |
$0.02B |
5.42 |
| 2024-03-31 |
$0.12B |
$0.01B |
8.83 |
| 2023-12-31 |
$0.13B |
$0.05B |
2.43 |
| 2023-09-30 |
$0.11B |
$0.07B |
1.53 |
| 2023-06-30 |
$0.11B |
$0.11B |
1.03 |
| 2023-03-31 |
$0.07B |
$0.14B |
0.49 |
| 2022-12-31 |
$0.07B |
$0.17B |
0.41 |
| 2022-09-30 |
$0.07B |
$0.14B |
0.50 |
| 2022-06-30 |
$0.05B |
$0.16B |
0.31 |
| 2022-03-31 |
$0.05B |
$0.19B |
0.29 |
| 2021-12-31 |
$0.06B |
$0.22B |
0.29 |
| 2021-09-30 |
$0.06B |
$0.21B |
0.31 |
| 2021-06-30 |
$0.05B |
$0.18B |
0.25 |
| 2021-03-31 |
$0.05B |
$0.20B |
0.24 |
| 2020-12-31 |
$0.06B |
$0.17B |
0.33 |
| 2020-09-30 |
$0.05B |
$0.07B |
0.70 |
| 2020-06-30 |
$0.05B |
$0.10B |
0.51 |
| 2020-03-31 |
$0.05B |
$0.12B |
0.41 |
| 2019-12-31 |
$0.05B |
$0.13B |
0.37 |
| 2019-09-30 |
$0.05B |
$0.16B |
0.33 |
| 2019-06-30 |
$0.05B |
$0.18B |
0.25 |
| 2019-03-31 |
$0.04B |
$0.13B |
0.33 |
| 2018-12-31 |
$0.04B |
$0.15B |
0.27 |
| 2018-09-30 |
$0.04B |
$0.07B |
0.56 |
| 2018-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-12-31 |
$0.01B |
$0.04B |
0.11 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
